Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma:

Patients: Inclusion Criteria: * Benign meningioma (grade I), or atypical meningioma (grade II) * Histologic proven of benign meningioma, atypical meningioma or unequivocal radiological diagnosis of skull base meningioma if biopsy is recused. * Indication of irradiation validated by a multidisciplinary meeting * Age \>20 years and \<65 years * Expected overall survival \>10 years * Adjuvant or exclusive irradiation is allowed. * Signed informed consent form * WHO Performance status equal to 0 or 1 * Patient affiliated to the French social health insurance * Patient whose neuropsychological abilities allow to follow the requirements of the protocol Exclusion Criteria: * Patient with mutation in a known predisposition gene (NF-2, SMARCE-1). * Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease, organic psychosis (other than dementia), or schizophrenia. * Other localization than skull base meningioma * Histology/radiological features rather different than grade I-II meningioma * Histologic proven grade III meningioma * Uncontrolled epilepsy * Contraindication to MRI * Patient with a history of brain irradiation. * Patient with a history of cancer in the last five years (excluding skin baso-cellular carcinoma) * Pregnant/breastfeeding woman * Any geographical conditions, social and associated psychopathology that may compromise the patient's ability to participate in the study * Participation in a therapeutic trial evaluating a radiotherapy schedule or a new drug or combination for less than 30 days * Patient deprived of freedom or under guardianship * Hypersensibility to Gadolinium Participants free of brain disease or cancer history: Inclusion Criteria: * Subject without any history of neurological disease (cerebral stroke, epilepsy, Intra cranial Neurosurgery procedure, meningioma, pituitary adenoma, Parkinson disease,Dementia…) or absence of personality disorders and progressive psychiatric pathology * Age \>20 years and \<65 years * Signed informed consent form * WHO Performance status equal to 0 or 1 * Subject affiliated to the French social health insurance * Subject whose neuropsychological abilities allow to follow the requirements of the protocol * No major cognitive disorder that may compromise the realization of cognitive evaluations, defined as a MoCA score in accordance with the threshold depending on age and educational level according to the GRECOGVASC normative data Non-inclusion criteria * Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease, organic psychosis (other than dementia), or schizophrenia * History of epilepsy with antiepileptic drug * Subject with a history of brain irradiation * Subject with a history of cancer in the last five years (Excluding skin baso-cellular carcinoma) * Pregnant/breastfeeding woman * Any geographical conditions, social and associated psychopathology that may compromise the subject's ability to participate in the study * Participation in a therapeutic trial - Subject deprived of freedom or under guardianship